All News

Found 104 articles

• Sanofi Creeps Up On Biogen’s MS Market Share

  12/2/2015

• In Largest M&A Year, a Pfizer-Allergan Deal Could Lead to a Pfizer Breakup

  11/10/2015

• Oncobiologics Pushes Into Biosimilars Market with New Manufacturing Facility

  5/5/2015

• Amgen Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars

  4/24/2015

• Ducere Pharma to Relaunch Ex-Novartis AG Cruex Antifungal

  4/1/2015

• Celgene, Merck & Co. Prime Examples of Novel Science "Renaissance," Says VC

  1/30/2015

• Vernalis PLC Stumbles As Novartis AG Abandons Work On AUY922

  12/19/2014

• GlaxoSmithKline Abandons Planned Sale Of Established Products Portfolio

  12/5/2014

• Analysts Believe Vulnerable GlaxoSmithKline May Be Pfizer's Plan B

  8/6/2014

• Novartis AG Abandons $600 Million Purchase Of Gamida Cell Ltd.

  5/5/2014

• BioSpace's Top 10 Most Popular Biotech Stories For April 2014

  5/1/2014

• GenVec Inc. Abandons Dissolution Plans, Replaces CEO

  9/4/2013

• Marina Biotech, Inc. Announces Year-to-Date 2012 Financial Results

  12/6/2012

• GlobalData Release: Heavyweight Battle: Buyer-Versus-Supplier Showdown in Childhood Vaccines

  8/16/2012

• Novartis AG to Shut Down Brain Research Facility; Redirects Psychiatric Efforts to Genetics

  12/8/2011

• NuPathe Inc. Strengthens Commercial Team

  5/24/2011

• Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management

  11/9/2010

• Ipsen In 3 Deals Worth $450M; Company to Build A Fully-Fledged Commercial Presence In North America -- $404M Tercica, Inc. Merger Deal; Vernalis PLC To Sell Apokyn And U.S. Commercial Operations for $17.5M; Octagon Corp. to be Acquired

  6/5/2008

• Major Pharma Clinical Case Studies During 1st Quarter ExL Pharma Programs

  12/11/2007

• Ipsen Could Receive 125 Million if Novartis Corporation (Jobs) Exercises BA058 Option

  9/17/2007